Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: Part 2, optimization for blood pressure reduction in spontaneously hypertensive rats

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 17, 2010, Pages 5153-5156

  Ginn, John D ^a   Bosanac, Todd ^a   Chen, Rhonda ^a   Cywin, Charles ^a   Hickey, Eugene ^a   Kashem, Mohammed ^a   Kerr, Steven ^a   Kugler, Stanley ^a   Li, Xiang ^a   Prokopowicz III, Anthony ^a   Schlyer, Sabine ^a   Smith, James D ^a   Turner, Michael R ^a   Wu, Frank ^a   Young, Erick R R ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Rho kinase inhibitors

Indexed keywords

2H ISOQUINOLIN 1 ONE DERIVATIVE; ISOQUINOLINE DERIVATIVE; PHENYLGLYCINE; PIPERIDINE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; DRUG METABOLISM; DRUG STABILITY; ENZYME INHIBITION; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD PRESSURE; ISOQUINOLINES; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED SHR; RHO-ASSOCIATED KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 77955660450     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.014     Document Type: Article

References (30)

1. N. Wettschureck, and S. Offermanns J. Mol. Med. 80 2002 629
2. B. Mueller, H. Mack, and N. Teusch Nat. Rev. Drug Disc. 4 2005 387
3. M. Oka, K.A. Fagan, P.L. Jones, and I.F. McMurtry Br. J. Pharmacol. 155 2008 444
4. M. Amano, Y. Fukata, and K. Kaibuchi Exp. Cell Res. 261 2000 44
5. T. Schroeter, E. Griffin, A. Weiser, Y. Feng, and P. LoGrasso Biochem. Biophys. Res. Commun. 374 2008 356
6. K. Riento, and A.J. Ridley Nat. Rev. Mol. Cell Biol. 4 2003 446
7. M. Sugimoto, M. Nakayama, T.M. Goto, M. Amano, K. Komori, and K. Kaibuchi Biochem. Biophys. Res. Commun. 361 2007 462
8. R.L. Simoes, and I.M. Fierro J. Immunol. 175 2005 1843
9. G. Bardi, V. Niggli, and P. Loetscher FEBS Lett. 542 2003 79
10. V. Niggli FEBS Lett. 445 1999 69
11. M. Ruperez, E. Sanchez-Lopez, L. Blanco-Colio, V. Esteban, J. Rodriguez-Vita, J. Plaza, J. Egido, and M. Ruiz-Ortega Kidney Int. 68 2005 539
12. K.A. Harvey, C.N. Paranavitana, G.P. Zaloga, and R.A. Siddiqui J. Cell. Physiol. 211 2007 353
13. M. Amano, K. Chihara, K. Kimura, Y. Fukata, N. Nakamura, Y. Matsuura, and K. Kaibuchi Science 275 1997 1308
14. K. Katoh, Y. Kano, and S. Ookawara Genes Cells 12 2007 623
15. S. Koshikawa, T. Nishikimi, C. Inaba, K. Akimoto, and H. Matsuoka J. Hypertens. 26 2008 1837
16. A. Nohria, M.E. Grunert, Y. Rikitake, K. Noma, A. Prsic, P. Ganz, J.K. Liao, and M.A. Creager Circ. Res. 99 2006 1426
17. K. Nagatoya, T. Moriyama, N. Kawada, M. Takeji, S. Oseto, T. Murozono, A. Ando, E. Imai, and M. Hori Kidney Int. 61 2002 1684
18. R.A. Stavenger Annu. Rep. Med. Chem. 43 2008 87
19. K. Goodman, H. Cui, S. Dowdell, R. Gaitanopoulos, C. Sehon, R. Stavenger, G. Wang, A. Viet, W. Xu, G. Ye, S. Semus, C. Evans, H. Fries, L. Jolivette, R. Kirkpatrick, E. Dul, S. Khandekar, T. Yi, D. Jung, L. Wright, G. Smith, D. Behm, R. Bentley, C. Doe, E. Hu, and D. Lee J. Med. Chem. 50 2007 6
20. R. Stavenger, H. Cui, S. Dowdell, R. Franz, D. Gaitanopoulos, K. Goodman, M. Hilfiker, R. Ivy, J. Leber, J. Marino, H. Oh, A. Viet, W. Xu, G. Ye, D. Zhang, Y. Zhao, L. Jolivetter, M. Head, S. Semus, P. Elkins, R. Kirkpatrick, E. Dul, S. Khandekar, T. Yi, D. Jung, L. Wright, G. Smith, D. Behm, C. Doe, R. Bentley, Z. Chen, E. Hu, and D. Lee J. Med. Chem. 50 2007 2
21. F. Wu, F. Buttner, R. Chen, E. Hickey, S. Jakes, P. Kaplita, M. Kashem, S. Kerr, S. Kugler, Z. Paw, A. Prokopowicz, C. Shih, R. Snow, E. Young, and C. Cywin Bioorg. Med. Chem. Lett. 20 2010 3235
22. Two isoforms of Rho-kinase (ROCK1 and ROCK2) are known and share >90% homology in the kinase domain. No significant differences in the SAR of the isoquinolone series between the two isoforms observed.
23. C. Doe, R. Bentley, D.J. Behm, R. Lafferty, R. Stavenger, D. Jung, M. Bamford, T. Panchal, E. Grygielko, L.L. Wright, G.K. Smith, Z. Chen, C. Webb, S. Khandekar, T. Yi, R. Kirkpatrick, E. Dul, L. Jolivette, J.P. Marino Jr., R. Willette, D. Lee, and E. Hu J. Pharmacol. Exp. Ther. 320 2007 89
24. D. Veber, S. Johnson, H. Cheng, B. Smith, K. Ward, and K. Kopple J. Med. Chem. 45 2002 2615
25. G. Smith, and T. Sivakus J. Org. Chem. 48 1983 627
26. D. Rijkers, H. Adams, H. Hemker, and G. Tesser Tetrahedron 51 1995 11235
27. 50 were determined for PRKG1 (230 nM), PRKCL2 (500 nM), p70S6 K (180 nM), and MSK2 (480 nM).
28. PDB ID: 3NCZ.
29. Rat PK data was obtained from an IV cassette study (n = 3, 0.2 mg/kg) followed by an oral leg (n = 1, 10 mg/kg) in male Sprague-Dawley rats.
30. A recent report from researchers at GSK demonstrated that upon chronic dosing of a Rho-kinase inhibitor the bp lowering effects diminished over time. The efficacy of compound 20 has not been examined in similar multi-dose studies. Goodman, K.; Dowdell, S.; Gaitanopoulos, D.; Ivy, R.; Sehon, C.; Stavenger, R.; Wang, G.; Viet, A.; Xu, W.; Ye, G.; Semus, S.; Evans, C.; Fries, H.; Jolivette, L.; Jung, D.; Wright, L.; Smith, G.; Behm, D.; Bentley, R.; Doe, C.; Hu, E.; Lee, D. 238th ACS National Meeting, Washington, DC, Aug 16, 2009; paper MEDI 252.